Fortress Biotech, Inc.

  • Home
  • About
    • Overview
    • Business Development
    • Management Team
    • Board of Directors
    • FAQ
  • Programs
    • Pipeline
    • Marketed Products
    • Publications
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Resources
  • Contact
  • Careers
  • Accessibility Statement

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Avenue Therapeutics Receives Notices of Allowance for Patent Applications Covering Methods of Administration for Intravenous Tramadol

Jan 03, 2017

Fortress Biotech Announces Publication on MB‐101 (IL13Rα2‐specific CAR T cells) for the Treatment of Glioblastoma in New England Journal of Medicine

Dec 28, 2016

Clinical and Pre-Clinical Data on Mustang Bio’s MB-101 (IL13Rα2-specific CAR T cells) for the Treatment of Glioblastoma (GBM) Presented at the 21st Annual Meeting and Education Day of the Society for Neuro-Oncology

Nov 21, 2016

Fortress Biotech Reports Third Quarter 2016 Financial Results and Recent Corporate Highlights

Nov 09, 2016

Fortress Biotech Forms New Subsidiary, Cellvation, Inc., to Develop Novel Therapies for the Treatment of Traumatic Brain Injury

Nov 07, 2016

Journey Medical Corporation Launches Targadox™ Oral Immediate-Release Tablet for Treatment of Severe Acne

Oct 17, 2016

Checkpoint Therapeutics Initiates Phase 1/2 Study of CK-101 – A Novel Third-Generation EGFR Inhibitor

Oct 03, 2016

Checkpoint Therapeutics to Present at the Ladenburg Thalmann 2nd Annual Healthcare Conference

Sep 23, 2016

Fortress Biotech Completes Tender Offer for Shares of National Holdings Corporation

Sep 12, 2016

Checkpoint Therapeutics Announces Acceptance of IND Application for CK-101 – A Novel Third Generation EGFR Inhibitor

Aug 11, 2016
RSS
  • Prev
    • 1...
    • 34
    • 35
    • 36
    • 37
    • 38
    • 39
    • 40
    • 41
    • 42
    • 43
    Next

    Fortress Biotech programs include product candidates in development at Fortress, its majority-owned and majority-controlled partner companies and entities in which it holds minority ownership positions.

    © 2022 Fortress Biotech, Inc. All Rights Reserved.
    Facebook Twitter Linkedin
    Accessibility Statement Privacy Policy Disclaimer Sitemap